PMID- 35363325
OWN - NLM
STAT- MEDLINE
DCOM- 20220407
LR  - 20220509
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 6
DP  - 2022 Mar
TI  - Short period-administration of myo-inositol and metformin on hormonal and 
      glycolipid profiles in patients with polycystic ovary syndrome: a systematic 
      review and updated meta-analysis of randomized controlled trials.
PG  - 1792-1802
LID - 28322 [pii]
LID - 10.26355/eurrev_202203_28322 [doi]
AB  - OBJECTIVE: This meta-analysis aims to perform an updated meta-analysis to 
      evaluate myo-inositol (myo-ins) and the classical insulin sensitizer metformin in 
      terms of efficacy and safety for treating women with polycystic ovary syndrome 
      (PCOS). MATERIALS AND METHODS: A comprehensive literature search was performed 
      using PubMed, Web of Science, EMBASE, Cochrane Library, PhRMA Clinical Study 
      Results, Wan Fang, and CNKI databases; the database was searched from inception 
      to June 2021. The random effects model was chosen to synthesize the effect sizes 
      of individual trails. The registration number is CRD42021239786. RESULTS: Nine 
      randomized controlled trials (RCTs) and 612 patients were included in the 
      analysis. Compared with metformin, myo-ins might be more effective in lowering 
      triglycerides (TG) levels (SMD -0.49, 95% CI -0.74 to -0.24, p=0.0001, I2 = 0%) 
      and avoiding side effects (RR=0.14, 95% CI 0.08-0.24, p<0.00001, I2 = 2%), while 
      no significant differences were observed in other relevant indexes, such as total 
      testosterone (TT) and sex-hormone binding globulin (SHBG). CONCLUSIONS: Compared 
      with metformin, the suitable supplemental dosage of myo-ins may be helpful in 
      lowering levels of TG and avoiding adverse events (AEs).
FAU - Zhang, J-Q
AU  - Zhang JQ
AD  - Department of Endocrinology, Shengjing Hospital, China Medical University, 
      Shenyang, Liaoning province, PR China. hebing7557@163.com.
FAU - Xing, C
AU  - Xing C
FAU - He, B
AU  - He B
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Glycolipids)
RN  - 0 (Hypoglycemic Agents)
RN  - 4L6452S749 (Inositol)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Female
MH  - Glycolipids
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Inositol/therapeutic use
MH  - *Metformin/therapeutic use
MH  - *Polycystic Ovary Syndrome/drug therapy/metabolism
MH  - Randomized Controlled Trials as Topic
EDAT- 2022/04/02 06:00
MHDA- 2022/04/08 06:00
CRDT- 2022/04/01 12:21
PHST- 2022/04/01 12:21 [entrez]
PHST- 2022/04/02 06:00 [pubmed]
PHST- 2022/04/08 06:00 [medline]
AID - 28322 [pii]
AID - 10.26355/eurrev_202203_28322 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 Mar;26(6):1792-1802. doi: 
      10.26355/eurrev_202203_28322.